Transparent Thinking Blog

TrialAssure cubes divider
Policy 0070 submissions pending suspension in Europe – DIA Communities Due to EMA’s relocation from London to Amsterdam, the “launch of new procedures (related to clinical data publication under Policy 0070) will be temporarily suspended already as of 1 August 2018,” according to an email shared by Melanie Carr, Head of Stakeholders and Communication Division and Head of Corporate Stakeholders Department ad interim, European Medicines Agency (EMA). It is noted that all redaction proposal packages submitted after July 31st will be temporarily suspended. A press release with full details is said to be released next week.

This week in transparency news: July 14 – July 20, 2018

Read More
bioethics international good pharma scorecard gps disclosure clinical trial transparency trialassure

This week in transparency news: July 7 – July 13, 2018

Read More
The U.S. Senate had voted in favor of an opioid bill that expands Open Payments to include payments made to Nurse Practitioners, Physician Assistants, Nurse Midwifes, Nurse Anesthetists, and Clinical Nurse Specialists, in addition to current physician reporting requirements. This will go into effect beginning January 1, 2022. Inconsistent Clinical Trial Disclosure and Lack of Compliance Across Big Pharma

This week in transparency news: June 30 – July 6, 2018

Read More
bioethics international good pharma scorecard gps disclosure clinical trial transparency trialassure

Good Pharma Scorecard: Improvements Seen in Clinical Trial Transparency Compliance

Read More

Research Organizations Commit to Full Transparency

Read More

Major Legal Ruling Announced in Transparency Reporting: Agencies Want to See More Data Quicker (& Data for Non-Approved Drugs Too!)

Read More
The U.S. Senate had voted in favor of an opioid bill that expands Open Payments to include payments made to Nurse Practitioners, Physician Assistants, Nurse Midwifes, Nurse Anesthetists, and Clinical Nurse Specialists, in addition to current physician reporting requirements. This will go into effect beginning January 1, 2022. Inconsistent Clinical Trial Disclosure and Lack of Compliance Across Big Pharma

Inconsistent Clinical Trial Disclosure and Lack of Compliance Across Big Pharma

Read More
joe archer ed miseta clinical leader magazine life science leader magazine drug information association annual event DIA 2013 Clinical Trial Disclosure Transparency Services Solutions Future compliance with regulations expert software solution pharma

VIDEO: Clinical Trial Disclosures; More Transparency in the Future

Read More

Traveling the Road to Clinical Trial Transparency

Read More
National Institute of Mental Health (NIMH) trialassure

Clinical Trial Disclosure: More “FDA” Needed in Past and Present Acts

Read More
Get in Touch

Looking to streamline your clinical trial disclosure and transparency efforts?

TrialAssure is ready to help your organization embark on a Transparency Transformation!

To learn more about the TrialAssure Transparency Suite, specific products, or our company, contact us below.

Sticky Side CTA Form